Christian Ramos-Jiménez

Dr. Christian Ramos-Jiménez

Psychiatry, McGill University, Montréal, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Brain Stimulation
Verified
Journal Article
Closed access
DODANIEL San Juan Orta
DANIEL San Juan Orta
DDDaniel Oswaldo Dávila-Rodríguez
Daniel Oswaldo Dávila-Rodríguez
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
MGManuel Sánchez González
Manuel Sánchez González
SCSergio Mayorquín Carranza
Sergio Mayorquín Carranza
DADavid J. Anschel
David J. Anschel

1 July 2020 in Clinical Neurophysiology
Verified
Journal Article
Closed access
DODANIEL San Juan Orta
DANIEL San Juan Orta
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
CCCecilia Ximénez Camilli
Cecilia Ximénez Camilli
LRLuis Adrián de la Cruz Reyes
Luis Adrián de la Cruz Reyes
EGEnya Gabriela Aguirre Galindo
Enya Gabriela Aguirre Galindo
PKPaulo Andre Teixeira Kimaid
Paulo Andre Teixeira Kimaid

1 February 2025 in JAMA Psychiatry
Verified
Journal Article
Closed access
PDF file
MBM. Belen Blasco
M. Belen Blasco
KAKankana Nisha Aji
Kankana Nisha Aji
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
ILIlana Ruth Leppert
Ilana Ruth Leppert
CTChristine Lucas Tardif
Christine Lucas Tardif
RMRomina Mizrahi
Romina Mizrahi
Importance: Synaptic dysfunction is involved in schizophrenia pathophysiology. However, whether in vivo synaptic density is reduced in early stages of psychosis, including its high-risk states, remains unclear.Objective: To investigate whether synaptic density (synaptic vesicle glycoprotein 2A [SV2A] binding potential) is reduced in first-episode psychosis (FEP) and in clinical high risk (CHR) and investigate the effect of cannabis use on synaptic density and examine its relationship with psychotic symptoms and gray matter microstructure across groups.Design, Setting, and Participants: This cross-sectional study was performed in a tertiary care psychiatric hospital from July 2021 to October 2023. Participants were patients with antipsychotic-free or minimally exposed FEP or CHR and healthy controls with a clean urine drug screen (except cannabis).Main Outcomes and Measures: Synaptic density was quantified with dynamic 90-minute [18F]SynVesT-1 positron emission tomography (PET) scans across prioritized brain regions of interest (ROIs) delineated in individual magnetic resonance images (MRIs). Cannabis use was confirmed with urine drug screens. Gray matter microstructure was assessed using diffusion-weighted MRI to estimate neurite density.Results: A total of 49 participants were included, including 16 patients with FEP (mean [SD] age, 26.1 [4.6] years; 9 males and 7 females), 17 patients at CHR (mean [SD] age, 21.2 [3.5] years; 8 males and 9 females), and 16 healthy controls (mean [SD] age, 23.4 [3.6] years; 7 males and 9 females). Synaptic density was significantly different between groups (F2,273 = 4.02, P = .02, Cohen F = 0.17; ROI: F5,273 = 360.18, P < .01, Cohen F = 2.55) with a group × ROI interaction (F10,273 = 2.67, P < .01, Cohen F = 0.32). Synaptic density was lower in cannabis users (F1,272 = 5.31, P = .02, Cohen F = 0.14). Lower synaptic density across groups was associated with more negative symptoms (Positive and Negative Syndrome Scale negative scores: F1,81 = 4.31, P = .04, Cohen F = 0.23; Scale of Psychosis-Risk Symptoms negative scores: F1,90 = 4.12, P = .04, Cohen F = 0.21). SV2A binding potential was significantly associated with neurite density index (F1,138 = 6.76, P = .01, Cohen F = 0.22).Conclusions and Relevance: This study found that synaptic density reductions were present during the early stages of psychosis and its risk states and associated with negative symptoms. The implications of SV2A for negative symptoms in psychosis and CHR warrant further investigation. Future studies should investigate the impact of cannabis use on synaptic density in CHR longitudinally.

1 December 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
SLSalvador Vergara López
Salvador Vergara López
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
LRLuis Adrián de la Cruz Reyes
Luis Adrián de la Cruz Reyes
ARAxel Kevin Galindo Ruiz
Axel Kevin Galindo Ruiz
LALuis Armando Baigts Arriola
Luis Armando Baigts Arriola
DODANIEL San Juan Orta
DANIEL San Juan Orta

7 November 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
KAKankana Nisha Aji
Kankana Nisha Aji
NLNittha Lalang
Nittha Lalang
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
Reza RahimianReza Rahimian
Reza Rahimian
NMNaguib Mechawar
Naguib Mechawar
RMRomina Mizrahi
Romina Mizrahi

29 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
Christian Ramos-JiménezChristian Ramos-Jiménez
Christian Ramos-Jiménez
SPSarah Petkau
Sarah Petkau
RMRomina Mizrahi
Romina Mizrahi
Background: Astrocytic reactivity in substance use disorders (SUDs) has been extensively studied, yet the molecular effect of delta-9-tetrahydrocannabinol (∆9-THC, the main psychoactive compound in cannabis) on glial cells, especially astrocytes, remains poorly understood. Exploring ∆9-THC’s impact on astrocytic markers can provide insight into its effects on brain functions such as homeostasis, synaptic transmission, and response to neuronal injury. This systematic review synthesizes findings from studies investigating ∆9-THC’s impact on astrocytic markers. Methods: A systematic review was conducted using EMBASE, Medline, and PsychoInfo via the OvidSP platform. Studies reporting astrocytic markers following ∆9-THC exposure in animals and humans were included. Data were extracted from twelve eligible full-text articles, and the risk of bias was assessed using the Systematic Review Center for Laboratory Animal Experimentation. Results: This research identified several astrocytic markers, including glial fibrillary acidic protein (GFAP), nestin, and glutamate–aspartate transporter (GLAST). Both GFAP and nestin expressions increased in adulthood following adolescence and adult ∆9-THC exposure. An increase in GLAST expression was also noted during early development after ∆9-THC exposure. Conclusions: This review indicates varying levels of astrocytic reactivity to ∆9-THC across different developmental stages, including adolescence and adulthood. ∆9-THC appears to impact maturation, particularly during early developmental stages, and exhibits sex-dependent effects.